Metformin (the biguanidine group) is the basis of the treatment for type 2 diabetes mellitus. By increasing the receptor sensitivity to insulin, metformin suppresses the main pathogenesis factor of this disease - insulin resistance and restores the sensitivity of body tissues to insulin.
The drug normalizes lipid metabolism, is able to reduce body weight, delaying the glucose absorption in the gastrointestinal tract, and also due to a weak anorexigenic effect. It does not decrease blood sugar levels.
Glibenclamide (second generation sulfonylurea group) enhances the metformin efficacy by increasing the insulin production by pancreatic beta cells and increasing its release into the blood
Metformin and glibenclamide differ in mechanisms of action and complement each other's hypoglycemic activity.
The fixed combination of the drugs increases the adherence of patients to treatment due to the mutual enhancement of the therapeutic effect and more convenient use in one tablet.
Two dosages (glibenclamide 2.5 mg + metformin 500 mg and glibenclamide 5 mg + metformin 500 mg) allows choosing the best dosing schedule for each patient.
The fixed combination of metformin and a sulfonylurea drug in one tablet allows reducing the glycemia and HbA1c levels in situations where the target level of these indicators is not achieved by therapy with only one of the drugs.